A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Trial Profile

A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs RG 7636 (Primary)
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 01 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top